Pharmanta-Europesp. z o.o.

Manufacture of basic pharmaceutical products

KRS: NIP: REGON:

Overview

Status
Suspended
Registry date
2015-05-12
Share capital
150 000,00 PLN
Registered address
Warszawa, Poland

Financials

Filing timeliness

No financial statement for 2019 – the filing deadline has passed.

  • 2019not filed
  • 201815/07/2019
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2018.

Results vs industry

Revenue
This companyUSD 686.59kMedianUSD 164.14kAverageUSD 2.27m
Net profit
This companyUSD 28.74kMedianUSD 1.03kAverageUSD 108.21k
Operating costs
This companyUSD 657.66kMedianUSD 187.05kAverageUSD 2.07m
Assets
This companyUSD 181.36kMedianUSD 115.76kAverageUSD 1.52m

Authorized Representatives

Roman Pełkowski – President of the Management Board

Manner of representation

In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

OwnerSharesShare valueStake
300$40,518.64100%

Beneficial owners

Person

Bank accounts

Was a VAT taxpayer from 2015-05-22 to 2025-03-28.

Reason for removal: Art. 96 ust. 9 pkt 3 (data provided in the VAT-R registration form is false)

Debt

19 closed proceedings recorded in KRZ history.

Registration dateProceeding typeStatus
Jul 31, 2025
Discontinued enforcement proceedings
Closed
Jul 31, 2025
Discontinued enforcement proceedings
Closed
Jul 31, 2025
Discontinued enforcement proceedings
Closed
Jul 31, 2025
Discontinued enforcement proceedings
Closed
Jul 31, 2025
Discontinued enforcement proceedings
Closed

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282

Competitors

Name
Natur DayS.A.
Biotriosp. z o.o.
Nature's Voicesp. z o.o.
Pexon Polandsp. z o.o.
Munar PharmaS.A.
Bioresearch PharmaS.A.
Sanford Biotechsp. z o.o.
Cefeasp. z o.o.
Auxilius PharmaS.A.
Grupa FinepharmS.A.

Change history

DateEvent
2024-12-31Business suspended
2017-03-02Share capital change
2015-05-12Entered in the register

FAQ

Last updated: 2026-10-07